Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients
Severe persistent asthma causes a substantial morbidity and mortality burden and is frequently not well controlled, despite intensive guideline-based therapy. The unique monoclonal antibody approved for patients with severe allergic asthma is omalizumab: a recombinant humanised murine against IgE an...
Gespeichert in:
| Veröffentlicht in: | International journal of immunopathology and pharmacology Jg. 25; H. 2; S. 475 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
England
01.04.2012
|
| Schlagworte: | |
| ISSN: | 0394-6320 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Severe persistent asthma causes a substantial morbidity and mortality burden and is frequently not well controlled, despite intensive guideline-based therapy. The unique monoclonal antibody approved for patients with severe allergic asthma is omalizumab: a recombinant humanised murine against IgE antibodies. The aim of the present study is to investigate the effect of long-term anti-IgE on the thickening of the reticular basement membrane (RBM) and eosinophil infiltration in bronchial biopsies from patients with severe persistent allergic asthma. Biopsies were obtained from 11 patients with severe persistent allergic asthma before and after (12 months) treatment with omalizumab. RBM thickness and eosinophils were measured by using light microscope image analysis. A significant mean reduction in RBM thickness and eosinophil infiltration were measured after one-year omalizumab treatment. No correlation between eosinophil reduction and RBM thickness reduction was found. No correlation between each of the previous two parameters and clinical parameters was detected. In conclusion, our study showed that a substantial proportion of severe asthmatics reduced the original bronchial RBM thickness and eosinophil infiltration after one-year treatment with anti-IgE, thus emphasizing the possible role of omalizumab in affecting airway remodeling in severe persistent allergic asthma. |
|---|---|
| AbstractList | Severe persistent asthma causes a substantial morbidity and mortality burden and is frequently not well controlled, despite intensive guideline-based therapy. The unique monoclonal antibody approved for patients with severe allergic asthma is omalizumab: a recombinant humanised murine against IgE antibodies. The aim of the present study is to investigate the effect of long-term anti-IgE on the thickening of the reticular basement membrane (RBM) and eosinophil infiltration in bronchial biopsies from patients with severe persistent allergic asthma. Biopsies were obtained from 11 patients with severe persistent allergic asthma before and after (12 months) treatment with omalizumab. RBM thickness and eosinophils were measured by using light microscope image analysis. A significant mean reduction in RBM thickness and eosinophil infiltration were measured after one-year omalizumab treatment. No correlation between eosinophil reduction and RBM thickness reduction was found. No correlation between each of the previous two parameters and clinical parameters was detected. In conclusion, our study showed that a substantial proportion of severe asthmatics reduced the original bronchial RBM thickness and eosinophil infiltration after one-year treatment with anti-IgE, thus emphasizing the possible role of omalizumab in affecting airway remodeling in severe persistent allergic asthma. Severe persistent asthma causes a substantial morbidity and mortality burden and is frequently not well controlled, despite intensive guideline-based therapy. The unique monoclonal antibody approved for patients with severe allergic asthma is omalizumab: a recombinant humanised murine against IgE antibodies. The aim of the present study is to investigate the effect of long-term anti-IgE on the thickening of the reticular basement membrane (RBM) and eosinophil infiltration in bronchial biopsies from patients with severe persistent allergic asthma. Biopsies were obtained from 11 patients with severe persistent allergic asthma before and after (12 months) treatment with omalizumab. RBM thickness and eosinophils were measured by using light microscope image analysis. A significant mean reduction in RBM thickness and eosinophil infiltration were measured after one-year omalizumab treatment. No correlation between eosinophil reduction and RBM thickness reduction was found. No correlation between each of the previous two parameters and clinical parameters was detected. In conclusion, our study showed that a substantial proportion of severe asthmatics reduced the original bronchial RBM thickness and eosinophil infiltration after one-year treatment with anti-IgE, thus emphasizing the possible role of omalizumab in affecting airway remodeling in severe persistent allergic asthma.Severe persistent asthma causes a substantial morbidity and mortality burden and is frequently not well controlled, despite intensive guideline-based therapy. The unique monoclonal antibody approved for patients with severe allergic asthma is omalizumab: a recombinant humanised murine against IgE antibodies. The aim of the present study is to investigate the effect of long-term anti-IgE on the thickening of the reticular basement membrane (RBM) and eosinophil infiltration in bronchial biopsies from patients with severe persistent allergic asthma. Biopsies were obtained from 11 patients with severe persistent allergic asthma before and after (12 months) treatment with omalizumab. RBM thickness and eosinophils were measured by using light microscope image analysis. A significant mean reduction in RBM thickness and eosinophil infiltration were measured after one-year omalizumab treatment. No correlation between eosinophil reduction and RBM thickness reduction was found. No correlation between each of the previous two parameters and clinical parameters was detected. In conclusion, our study showed that a substantial proportion of severe asthmatics reduced the original bronchial RBM thickness and eosinophil infiltration after one-year treatment with anti-IgE, thus emphasizing the possible role of omalizumab in affecting airway remodeling in severe persistent allergic asthma. |
| Author | Riccio, A M Dal Negro, R W Micheletto, C De Ferrari, L Chiappori, A Canonica, G W Folli, C |
| Author_xml | – sequence: 1 givenname: A M surname: Riccio fullname: Riccio, A M organization: Allergy and Respiratory Diseases, DIMI, University of Genoa, Italy – sequence: 2 givenname: R W surname: Dal Negro fullname: Dal Negro, R W – sequence: 3 givenname: C surname: Micheletto fullname: Micheletto, C – sequence: 4 givenname: L surname: De Ferrari fullname: De Ferrari, L – sequence: 5 givenname: C surname: Folli fullname: Folli, C – sequence: 6 givenname: A surname: Chiappori fullname: Chiappori, A – sequence: 7 givenname: G W surname: Canonica fullname: Canonica, G W |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22697079$$D View this record in MEDLINE/PubMed |
| BookMark | eNo1kMtOwzAQRb0ooqX0B1ggL9kEbOfhZIkqXlKlbmAdTeIJMdhOsB0k-Ai-mVSU1egeHV3pzhlZuMEhIRecXXMu5Q1Lq6xIBeOCiZwxweWCrA4wOdAl2YTwxhjjLM3ykp-SpRBFJZmsVuRnb8Ho78lCQ-2gJgMRA2384Npeg6Eeo25n6mkDAS26SC3axoNDGnvdvjsMgYJTFIeg3TD22lDtOm2ih6gHNwca8BM90hF90CEeOsAY9K-6pRBib4GOszvzcE5OOjABN8e7Ji_3d8_bx2S3f3ja3u6SNstETJTKRSoh74qqKDOVgeKQim7eXrSohGxSpvIiT7mssOvKOQoEnqqukQXrWiHW5Oqvd_TDx4Qh1laHFo2Zdw1TqDkTrBSVzMpZvTyqU2NR1aPXFvxX_f9D8QvgA3jX |
| CitedBy_id | crossref_primary_10_1155_2018_9095275 crossref_primary_10_1186_2049_6958_9_23 crossref_primary_10_29262_ram_v67i7_777 crossref_primary_10_1080_14712598_2020_1751115 crossref_primary_10_1080_17476348_2016_1205490 crossref_primary_10_1111_all_16382 crossref_primary_10_2147_JAA_S324080 crossref_primary_10_1111_resp_14096 crossref_primary_10_3389_fphys_2023_1113100 crossref_primary_10_1016_j_anai_2014_06_004 crossref_primary_10_1183_13993003_01619_2023 crossref_primary_10_1016_j_jaip_2022_04_029 crossref_primary_10_1080_03007995_2017_1400961 crossref_primary_10_1097_ACI_0000000000000226 crossref_primary_10_1016_j_pupt_2017_03_004 crossref_primary_10_1183_13993003_01397_2023 crossref_primary_10_1183_16000617_00001715 crossref_primary_10_1186_s12948_015_0027_7 crossref_primary_10_1016_j_rmed_2018_06_021 crossref_primary_10_1586_17476348_2016_1111763 crossref_primary_10_3390_ijms20040875 crossref_primary_10_1016_j_imlet_2014_08_010 crossref_primary_10_1016_j_pupt_2020_101966 crossref_primary_10_3389_fmed_2017_00103 crossref_primary_10_1097_ACI_0000000000000161 crossref_primary_10_1016_j_jaci_2018_02_041 crossref_primary_10_1016_j_rmr_2016_07_006 crossref_primary_10_1080_17476348_2024_2380072 crossref_primary_10_1007_s40264_017_0522_5 crossref_primary_10_1016_S2213_2600_13_70128_0 crossref_primary_10_4168_aair_2023_15_2_119 crossref_primary_10_3390_children11020262 crossref_primary_10_1016_j_pupt_2018_11_002 crossref_primary_10_1186_1710_1492_9_41 crossref_primary_10_1186_1939_4551_7_17 crossref_primary_10_1177_1753466618810192 crossref_primary_10_1016_j_waojou_2022_100695 crossref_primary_10_1186_s13601_017_0143_1 crossref_primary_10_1016_j_pupt_2015_01_006 crossref_primary_10_1016_j_arbres_2024_09_007 crossref_primary_10_1371_journal_pone_0056015 crossref_primary_10_1016_j_smim_2019_101294 crossref_primary_10_1007_s40261_015_0267_9 crossref_primary_10_1016_j_anai_2024_09_023 crossref_primary_10_1111_all_15473 crossref_primary_10_3389_fimmu_2025_1531986 crossref_primary_10_1111_resp_14115 crossref_primary_10_1080_02770903_2021_1903917 crossref_primary_10_3390_vaccines10122068 crossref_primary_10_3109_01902148_2013_813610 crossref_primary_10_1183_13993003_02583_2021 crossref_primary_10_1097_MCP_0000000000000438 crossref_primary_10_1038_nrd3792 crossref_primary_10_5966_sctm_2013_0061 crossref_primary_10_1007_s40265_014_0250_4 crossref_primary_10_1007_s40265_013_0085_4 crossref_primary_10_1016_j_anai_2013_12_013 crossref_primary_10_1016_j_pharmthera_2016_10_016 crossref_primary_10_1007_s40265_023_01905_5 crossref_primary_10_4049_jimmunol_1601476 crossref_primary_10_1097_ACI_0000000000000044 crossref_primary_10_1371_journal_pone_0136549 crossref_primary_10_1586_17476348_2015_1000866 crossref_primary_10_3390_jcm13164750 crossref_primary_10_1183_20734735_018917 crossref_primary_10_3390_children9081253 crossref_primary_10_1080_24745332_2017_1295776 crossref_primary_10_1155_mi_5526526 crossref_primary_10_1183_16000617_0101_2015 crossref_primary_10_1517_17460441_2015_1048220 crossref_primary_10_1164_rccm_202408_1544OC crossref_primary_10_3390_diagnostics11010083 crossref_primary_10_1111_all_16459 crossref_primary_10_1080_02770903_2019_1585872 crossref_primary_10_1016_j_pupt_2012_09_005 crossref_primary_10_1111_all_13302 crossref_primary_10_3390_ijms26167692 crossref_primary_10_1080_17425255_2016_1248403 crossref_primary_10_1111_cea_13501 crossref_primary_10_1185_03007995_2013_821057 crossref_primary_10_3402_ecrj_v3_31813 crossref_primary_10_1016_j_anai_2021_03_023 crossref_primary_10_3390_jcm12196207 crossref_primary_10_1177_2040622316659863 crossref_primary_10_1111_pai_12272 crossref_primary_10_1186_s13052_019_0737_4 crossref_primary_10_1016_j_pupt_2014_01_007 crossref_primary_10_1186_s12931_020_01513_x crossref_primary_10_1177_1753466619841274 crossref_primary_10_1080_17460441_2018_1396315 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1177/039463201202500217 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| ExternalDocumentID | 22697079 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Italy |
| GeographicLocations_xml | – name: Italy |
| GroupedDBID | --- -TM 0R~ 53G 54M 5GY 7X7 8FI 8FJ AABMB AACKU AADUE AAGGD AAJIQ AAJPV AANSI AAPEO AAQXH AARDL AARIX AASGM AAVDI AAXOT AAYTG AAZBJ ABAWP ABDWY ABEIX ABFWQ ABHKI ABJIS ABKRH ABOCM ABPGX ABQKF ABQNX ABQXT ABRHV ABUWG ABVFX ABVVC ABYTW ACARO ACDSZ ACDXX ACFMA ACGBL ACGFS ACLHI ACOFE ADBBV ADEIA ADMPF ADOGD ADTBJ ADUKL ADZZY AENEX AEQLS AEUHG AEWDL AEXFG AEXNY AFCOW AFEET AFFZS AFKRA AFKRG AFRWT AFUIA AGNHF AIGRN AJABX AJEFB AJMMQ AJSCY AJUZI ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS ARTOV AUTPY AYAKG B8M BCNDV BDDNI BENPR BKSCU BPHCQ BSEHC BVXVI CBRKF CCPQU CDWPY CFDXU CGR CORYS CQQTX CUTAK CUY CVF DC- DC. DOPDO EBS ECM EIF EJD EMOBN F5P FYUFA GROUPED_DOAJ H13 HMCUK HYE J8X K.F M4V MK0 NPM O9- OK1 P2P PHGZT PIMPY PQQKQ Q1R ROL RPM SAUOL SCDPB SFC SV3 UKHRP ZONMY ZPPRI ZRKOI ZSSAH 7X8 ACHEB SCNPE |
| ID | FETCH-LOGICAL-c442t-dd5237a5f69684d4ad1a32f5006ced27b30d5653179eff8b302ea13dfb760fc22 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 103 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000305879500017&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0394-6320 |
| IngestDate | Thu Oct 02 08:01:39 EDT 2025 Thu Apr 03 07:08:22 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c442t-dd5237a5f69684d4ad1a32f5006ced27b30d5653179eff8b302ea13dfb760fc22 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 22697079 |
| PQID | 1020829748 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1020829748 pubmed_primary_22697079 |
| PublicationCentury | 2000 |
| PublicationDate | 2012-04-01 |
| PublicationDateYYYYMMDD | 2012-04-01 |
| PublicationDate_xml | – month: 04 year: 2012 text: 2012-04-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | International journal of immunopathology and pharmacology |
| PublicationTitleAlternate | Int J Immunopathol Pharmacol |
| PublicationYear | 2012 |
| SSID | ssj0001034581 |
| Score | 2.2890494 |
| Snippet | Severe persistent asthma causes a substantial morbidity and mortality burden and is frequently not well controlled, despite intensive guideline-based therapy.... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 475 |
| SubjectTerms | Adult Anti-Asthmatic Agents - therapeutic use Antibodies, Anti-Idiotypic - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Asthma - diagnosis Asthma - drug therapy Asthma - immunology Asthma - pathology Basement Membrane - drug effects Basement Membrane - pathology Biopsy Bronchi - drug effects Bronchi - immunology Bronchi - pathology Eosinophils - drug effects Eosinophils - immunology Female Humans Italy Male Middle Aged Omalizumab Respiratory Hypersensitivity - diagnosis Respiratory Hypersensitivity - drug therapy Respiratory Hypersensitivity - immunology Respiratory Hypersensitivity - pathology Severity of Illness Index Time Factors Treatment Outcome |
| Title | Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/22697079 https://www.proquest.com/docview/1020829748 |
| Volume | 25 |
| WOSCitedRecordID | wos000305879500017&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEA7qinjx_VhfRPAaaJNsHycRcfHgrntQ2VtJk5Rd3D5sdz34I_zNzrRd9iQIXgoJpLTJl8mXyWQ-Qm56nvGVVj6LYZPMpDQhC2NXMSOllpJLzWsdsrcnfzgMxuNw1DrcqjascmkTa0Ntco0-cpjdvL4GKoPb4oOhahSerrYSGuukI4DKIKr9cbDysThC9mqdUkeEknmCO8t7M5hzCeqwyuXIA5Cb_84y69Wmv_vf79wjOy3PpHcNMPbJms0OyNagPUk_JN_PKTDwr0WqYprmBkW8bEXjMs8w-HlG68uNGKJKcZ1DFyJNbQpb68xSDJF_RxNJVWaozatplheT6YwCWqezNg8vFCisura0tECfHKAJ3oHKLSUYW6qq-SRVtE3rWh2R1_7Dy_0ja7UZGA7hnBkDO1hf9RJMriONVMZVgifQj562hvuxcAxwRWAnoU2SAIrcKleYJPY9J9GcH5ONLM_sKaEh1FqpjdRhIj3pKaudmMci8IzyuRVdcr3s6Qiwjwca8K_5oopWfd0lJ81wRUWTpCMCWhli9r-zP7Q-J9sIgyYg54J0Epj59pJs6s_5tCqvalDBczga_AA6qdoc |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Omalizumab+modulates+bronchial+reticular+basement+membrane+thickness+and+eosinophil+infiltration+in+severe+persistent+allergic+asthma+patients&rft.jtitle=International+journal+of+immunopathology+and+pharmacology&rft.au=Riccio%2C+A+M&rft.au=Dal+Negro%2C+R+W&rft.au=Micheletto%2C+C&rft.au=De+Ferrari%2C+L&rft.date=2012-04-01&rft.issn=0394-6320&rft.volume=25&rft.issue=2&rft.spage=475&rft_id=info:doi/10.1177%2F039463201202500217&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0394-6320&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0394-6320&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0394-6320&client=summon |